Kronos Bio Corporation (KRON) - Gross Profit Margin

Official company branding of Kronos Bio Inc (KRON)

Kronos Bio, Inc. (KRON) focuses on developing targeted cancer therapies for segments with a critical lack of treatment options. The GURU.Markets terminal displays a gross margin chart, where 82.70 represents the latest metric reading. Business growth relies on the expansion of CDK9 inhibitors through B2B partnerships, although the path to success is constrained by colossal clinical trial costs and stringent patent laws.

KRON (Kronos Bio Corporation) Return on Gross Profit history from 07/04/2022 to 06/28/2025

Financial and market metric breakdowns for Kronos Bio Inc (KRON)

- market price and analyst price targets:
Basic company analysis:Kronos Bio (KRON)
Manufactured products of Kronos Bio

Investors utilize cost management efficiency filtering to select fundamentally resilient assets. Gross margin determines the profit share after deducting direct production costs, demonstrating a business's ability to generate resources for growth. In the case of Kronos Bio, Inc. (KRON), high production margins confirm the return on investment in an elite staff of biologists conducting oncology research.